Scott E. Snyder

Scott E. Snyder

Auto-generated profile, based on publicly available information

Scott E. Snyder

Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2015 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
BHBao Hu
Bao Hu
AVAmy L. Va̅vEre
Amy L. Va̅vEre
KNKiel D. Neumann
Kiel D. Neumann
BSBarry L. Shulkin
Barry L. Shulkin
SDStephen G. DiMagno
Stephen G. DiMagno
SSScott E. Snyder
Scott E. Snyder

14 June 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
EBElizabeth R. Butch
Elizabeth R. Butch
PMPaul E. Mead
Paul E. Mead
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
HTHeather Tillman
Heather Tillman
ESElizabeth Stewart
Elizabeth Stewart
SSScott E. Snyder
Scott E. Snyder
The cell membrane glycolipid GD2 is expressed by multiple solid tumors, including 88% of osteosarcomas and 98% of neuroblastomas. However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on 99%, P < 0.05). These results support the utility of GD2 imaging with PET to measure GD2 expression in osteosarcoma and thus maximize the clinical impact of anti-GD2 immunotherapy. Significance: In situ assessment of all GD2-positive osteosarcoma sites with a novel PET radiotracer could significantly impact anti-GD2 immunotherapy patient selection and enable noninvasive probing of correlations between target expression and therapeutic response.

11 January 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
JLJohn Thomas Lucas
John Thomas Lucas
NSNick Serrano
Nick Serrano
HKHyun Kim
Hyun Kim
XLXingyu Li
Xingyu Li
SSScott E. Snyder
Scott E. Snyder
BSBarry L. Shulkin
Barry L. Shulkin

23 December 2015 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
KNKiel D. Neumann
Kiel D. Neumann
LQLinlin Qin
Linlin Qin
AVAmy L. Vāvere
Amy L. Vāvere
BSBin Shen
Bin Shen
ZMZheng Miao
Zheng Miao
SDStephen G. DiMagno
Stephen G. DiMagno

22 October 2018 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
AVAmy L. Vāvere
Amy L. Vāvere
KNKiel D. Neumann
Kiel D. Neumann
EBElizabeth R. Butch
Elizabeth R. Butch
BHBao Hu
Bao Hu
SDStephen G. DiMagno
Stephen G. DiMagno
SSScott E. Snyder
Scott E. Snyder

31 March 2023
Verified
Other
Open access
EBElizabeth R. Butch
Elizabeth R. Butch
PMPaul E. Mead
Paul E. Mead
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
HTHeather Tillman
Heather Tillman
ESElizabeth Stewart
Elizabeth Stewart
SSScott E. Snyder
Scott E. Snyder
The cell membrane glycolipid GD2 is expressed by multiple solid tumors, including 88% of osteosarcomas and 98% of neuroblastomas. However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on <50% of the individual cells, while some tumors are essentially GD2-negative. Anti-GD2 immunotherapy is the current standard of care for high-risk neuroblastoma, but its application to recurrent osteosarcomas, for which no effective therapies exist, has been extremely limited. This is, in part, because the standard assays to measure GD2 expression in these heterogeneous tumors are not quantitative and are subject to tissue availability and sampling bias. To address these limitations, we evaluated a novel, sensitive radiotracer [64Cu]Cu-Bn-NOTA-hu14.18K322A to detect GD2 expression in osteosarcomas (six patient-derived xenografts and one cell line) in vivo using positron emission tomography (PET). Tumor uptake of the radiolabeled, humanized anti-GD2 antibody [64Cu]Cu-Bn-NOTA-hu14.18K322A was 7-fold higher in modestly GD2-expressing osteosarcomas (32% GD2-positive cells) than in a GD2-negative tumor (9.8% vs. 1.3% of the injected dose per cc, respectively). This radiotracer also identified lesions as small as 29 mm3 in a 34% GD2-positive model of metastatic osteosarcoma of the lung. Radiolabeled antibody accumulation in patient-derived xenografts correlated with GD2 expression as measured by flow cytometry (Pearson r = 0.88, P = 0.01), distinguishing moderately GD2-expressing osteosarcomas (32%–69% GD2-positive cells) from high GD2 expressors (>99%, P < 0.05). These results support the utility of GD2 imaging with PET to measure GD2 expression in osteosarcoma and thus maximize the clinical impact of anti-GD2 immunotherapy.Significance:In situ assessment of all GD2-positive osteosarcoma sites with a novel PET radiotracer could significantly impact anti-GD2 immunotherapy patient selection and enable noninvasive probing of correlations between target expression and therapeutic response.